TY  - JOUR
AU  - Roksandić Milenković, M.
AU  - Klisić, Aleksandra
AU  - Ceriman, V.
AU  - Kotur-Stevuljević, Jelena
AU  - Savić-Vujović, Katarina
AU  - Mirkov, D.
AU  - Gajić, M.
AU  - Ilić, B.
AU  - Dimić, N.
AU  - Samardžić, N.
AU  - Jovanović, D.
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4171
AB  - Objective: The pathophysiological mechanisms of idiopathic pulmonary fibrosis (IPF) are not well elucidated. It is assumed that oxidative stress and inflammation are the key underlying culprits for its onset and progression. To gain deeper insight into these processes, we have evaluated several oxidative stress parameters, inflammation markers [i.e., high sensitivity C-reactive protein (hsCRP), serum amyloid A1 (SAA1)], soluble programmed cell death-ligand 1 (sPD-L1), and 25-hydroxyvitamin D [25(OH)D] in IPF patients. Patients and Methods: Biochemistry analyses were done in 30 consecutive IPF patients and 30 age and gender-matched healthy control group (CG). Results: IPF patients had significantly higher advanced oxidation protein products (p<0.001), pro-oxidant-antioxidant balance (p=0.010), total oxidative status (p<0.001), and ischemia modified albumin (p<0.001) compared to CG. Lower total antioxidant status and total sulfhydryl groups (tSGH) and significantly higher sPD-L1, hsCRP (p<0.001 for all), SAA1 proteins (p=0.014) and [25(OH)D] severe deficiency [11.0 (9.6-15.1) nmol/L] in IPF patients compared to CG were observed. Paraoxonase 1 activity and hsCRP level were lower, while tSHG and sPD-L1 were higher in IPF patients with more severe disease (i.e., II+III stage compared to I stage, p<0.05 for all). Conclusions: IPF patients are in a state of profound oxidative stress compared to healthy people. The inflammatory component of the disease was confirmed by higher hsCRP and SAA1, but lower [25(OH)D] in IPF than in healthy people. Also, higher levels of sPD-L1 in patients with IPF compared to healthy individuals suggest that sPD-L1 may have a significant role in immune response in IPF. © 2022 Verduci Editore s.r.l. All rights reserved.
PB  - Verduci Editore s.r.l
T2  - European Review for Medical and Pharmacological Sciences
T1  - Oxidative stress and inflammation parameters-novel biomarkers for idiopathic pulmonary fibrosis
VL  - 26
IS  - 3
SP  - 927
EP  - 934
DO  - 10.26355/eurrev_202202_28002
ER  - 

@article{
author = "Roksandić Milenković, M. and Klisić, Aleksandra and Ceriman, V. and Kotur-Stevuljević, Jelena and Savić-Vujović, Katarina and Mirkov, D. and Gajić, M. and Ilić, B. and Dimić, N. and Samardžić, N. and Jovanović, D.",
year = "2022",
abstract = "Objective: The pathophysiological mechanisms of idiopathic pulmonary fibrosis (IPF) are not well elucidated. It is assumed that oxidative stress and inflammation are the key underlying culprits for its onset and progression. To gain deeper insight into these processes, we have evaluated several oxidative stress parameters, inflammation markers [i.e., high sensitivity C-reactive protein (hsCRP), serum amyloid A1 (SAA1)], soluble programmed cell death-ligand 1 (sPD-L1), and 25-hydroxyvitamin D [25(OH)D] in IPF patients. Patients and Methods: Biochemistry analyses were done in 30 consecutive IPF patients and 30 age and gender-matched healthy control group (CG). Results: IPF patients had significantly higher advanced oxidation protein products (p<0.001), pro-oxidant-antioxidant balance (p=0.010), total oxidative status (p<0.001), and ischemia modified albumin (p<0.001) compared to CG. Lower total antioxidant status and total sulfhydryl groups (tSGH) and significantly higher sPD-L1, hsCRP (p<0.001 for all), SAA1 proteins (p=0.014) and [25(OH)D] severe deficiency [11.0 (9.6-15.1) nmol/L] in IPF patients compared to CG were observed. Paraoxonase 1 activity and hsCRP level were lower, while tSHG and sPD-L1 were higher in IPF patients with more severe disease (i.e., II+III stage compared to I stage, p<0.05 for all). Conclusions: IPF patients are in a state of profound oxidative stress compared to healthy people. The inflammatory component of the disease was confirmed by higher hsCRP and SAA1, but lower [25(OH)D] in IPF than in healthy people. Also, higher levels of sPD-L1 in patients with IPF compared to healthy individuals suggest that sPD-L1 may have a significant role in immune response in IPF. © 2022 Verduci Editore s.r.l. All rights reserved.",
publisher = "Verduci Editore s.r.l",
journal = "European Review for Medical and Pharmacological Sciences",
title = "Oxidative stress and inflammation parameters-novel biomarkers for idiopathic pulmonary fibrosis",
volume = "26",
number = "3",
pages = "927-934",
doi = "10.26355/eurrev_202202_28002"
}

Roksandić Milenković, M., Klisić, A., Ceriman, V., Kotur-Stevuljević, J., Savić-Vujović, K., Mirkov, D., Gajić, M., Ilić, B., Dimić, N., Samardžić, N.,& Jovanović, D.. (2022). Oxidative stress and inflammation parameters-novel biomarkers for idiopathic pulmonary fibrosis. in European Review for Medical and Pharmacological Sciences
Verduci Editore s.r.l., 26(3), 927-934.
https://doi.org/10.26355/eurrev_202202_28002

Roksandić Milenković M, Klisić A, Ceriman V, Kotur-Stevuljević J, Savić-Vujović K, Mirkov D, Gajić M, Ilić B, Dimić N, Samardžić N, Jovanović D. Oxidative stress and inflammation parameters-novel biomarkers for idiopathic pulmonary fibrosis. in European Review for Medical and Pharmacological Sciences. 2022;26(3):927-934.
doi:10.26355/eurrev_202202_28002 .

Roksandić Milenković, M., Klisić, Aleksandra, Ceriman, V., Kotur-Stevuljević, Jelena, Savić-Vujović, Katarina, Mirkov, D., Gajić, M., Ilić, B., Dimić, N., Samardžić, N., Jovanović, D., "Oxidative stress and inflammation parameters-novel biomarkers for idiopathic pulmonary fibrosis" in European Review for Medical and Pharmacological Sciences, 26, no. 3 (2022):927-934,
https://doi.org/10.26355/eurrev_202202_28002 . .

TY  - JOUR
AU  - Jovanović, Dragana
AU  - Roksandić-Milenković, Marina
AU  - Kotur-Stevuljević, Jelena
AU  - Ceriman, Vesna
AU  - Vukanić, Ivana
AU  - Samardžić, Natalija
AU  - Popević, Spasoje
AU  - Ilić, Branislav
AU  - Gajić, Milija
AU  - Simon, Marioara
AU  - Simon, Ioan
AU  - Spasojević-Kalimanovska, Vesna
AU  - Belić, Milica
AU  - Mirkov, Damjan
AU  - Šumarac, Zorica
AU  - Milenković, Vladislav
PY  - 2019
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3341
AB  - Background: The objective of this prospective study was to evaluate whether soluble programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) and serum amyloid A1 (SAA1) are potential diagnostic, predictive or prognostic biomarkers in lung cancer. Methods: Lung cancer patients (n=115) with advanced metastatic disease, 101 with non-small cell lung cancer, NSCLC (77 EGFR wild-type NSCLC patients on chemotherapy, 15 EGFR mutation positive adenocarcinoma patients, 9 patients with mPD-L1 Expression >= 50% NSCLC - responders to immunotherapy), and 14 patients with small cell lung cancer (SCLC) were examined. ELISA method was used to determine sPD-L1 and SAA1 concentrations in patients' plasma. Results: Significantly higher blood concentrations of sPD-L1 and SAA1 were noted in lung cancer patients compared with a healthy control group. In PD-L1 + NSCLC patients, a significantly higher sPD-L1 level was noticed compared to any other lung cancer subgroup, as well as the highest average SAA1 value compared to other subgroups. Conclusions: It seems that sPD-1/PD-L1 might be a potential biomarker, prognostic and/or predictive, particularly in patients treated with immunotherapy. Serum amyloid A1 has potential to act as a good predictor of patients' survival, as well as a biomarker of a more advanced disease, with possibly good capability to predict the course of disease measured at different time points.
PB  - Društvo medicinskih biohemičara Srbije, Beograd i Versita
T2  - Journal of Medical Biochemistry
T1  - Soluble sPD-L1 and serum amyloid A1 as potential biomarkers for lung cancer
VL  - 38
IS  - 3
SP  - 332
EP  - 341
DO  - 10.2478/jomb-2018-0036
ER  - 

@article{
author = "Jovanović, Dragana and Roksandić-Milenković, Marina and Kotur-Stevuljević, Jelena and Ceriman, Vesna and Vukanić, Ivana and Samardžić, Natalija and Popević, Spasoje and Ilić, Branislav and Gajić, Milija and Simon, Marioara and Simon, Ioan and Spasojević-Kalimanovska, Vesna and Belić, Milica and Mirkov, Damjan and Šumarac, Zorica and Milenković, Vladislav",
year = "2019",
abstract = "Background: The objective of this prospective study was to evaluate whether soluble programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1) and serum amyloid A1 (SAA1) are potential diagnostic, predictive or prognostic biomarkers in lung cancer. Methods: Lung cancer patients (n=115) with advanced metastatic disease, 101 with non-small cell lung cancer, NSCLC (77 EGFR wild-type NSCLC patients on chemotherapy, 15 EGFR mutation positive adenocarcinoma patients, 9 patients with mPD-L1 Expression >= 50% NSCLC - responders to immunotherapy), and 14 patients with small cell lung cancer (SCLC) were examined. ELISA method was used to determine sPD-L1 and SAA1 concentrations in patients' plasma. Results: Significantly higher blood concentrations of sPD-L1 and SAA1 were noted in lung cancer patients compared with a healthy control group. In PD-L1 + NSCLC patients, a significantly higher sPD-L1 level was noticed compared to any other lung cancer subgroup, as well as the highest average SAA1 value compared to other subgroups. Conclusions: It seems that sPD-1/PD-L1 might be a potential biomarker, prognostic and/or predictive, particularly in patients treated with immunotherapy. Serum amyloid A1 has potential to act as a good predictor of patients' survival, as well as a biomarker of a more advanced disease, with possibly good capability to predict the course of disease measured at different time points.",
publisher = "Društvo medicinskih biohemičara Srbije, Beograd i Versita",
journal = "Journal of Medical Biochemistry",
title = "Soluble sPD-L1 and serum amyloid A1 as potential biomarkers for lung cancer",
volume = "38",
number = "3",
pages = "332-341",
doi = "10.2478/jomb-2018-0036"
}

Jovanović, D., Roksandić-Milenković, M., Kotur-Stevuljević, J., Ceriman, V., Vukanić, I., Samardžić, N., Popević, S., Ilić, B., Gajić, M., Simon, M., Simon, I., Spasojević-Kalimanovska, V., Belić, M., Mirkov, D., Šumarac, Z.,& Milenković, V.. (2019). Soluble sPD-L1 and serum amyloid A1 as potential biomarkers for lung cancer. in Journal of Medical Biochemistry
Društvo medicinskih biohemičara Srbije, Beograd i Versita., 38(3), 332-341.
https://doi.org/10.2478/jomb-2018-0036

Jovanović D, Roksandić-Milenković M, Kotur-Stevuljević J, Ceriman V, Vukanić I, Samardžić N, Popević S, Ilić B, Gajić M, Simon M, Simon I, Spasojević-Kalimanovska V, Belić M, Mirkov D, Šumarac Z, Milenković V. Soluble sPD-L1 and serum amyloid A1 as potential biomarkers for lung cancer. in Journal of Medical Biochemistry. 2019;38(3):332-341.
doi:10.2478/jomb-2018-0036 .

Jovanović, Dragana, Roksandić-Milenković, Marina, Kotur-Stevuljević, Jelena, Ceriman, Vesna, Vukanić, Ivana, Samardžić, Natalija, Popević, Spasoje, Ilić, Branislav, Gajić, Milija, Simon, Marioara, Simon, Ioan, Spasojević-Kalimanovska, Vesna, Belić, Milica, Mirkov, Damjan, Šumarac, Zorica, Milenković, Vladislav, "Soluble sPD-L1 and serum amyloid A1 as potential biomarkers for lung cancer" in Journal of Medical Biochemistry, 38, no. 3 (2019):332-341,
https://doi.org/10.2478/jomb-2018-0036 . .

TY  - JOUR
AU  - Jovanović, Dragana
AU  - Milenković, Marina
AU  - Kotur-Stevuljević, Jelena
AU  - Marković, Jelena
AU  - Ceriman, Vesna
AU  - Kontić, Milica
AU  - Skodrić-Trifunović, Vesna
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3136
AB  - Background: Idiopathic pulmonary fibrosis (IPF) has common risk factors with cancer and significant similarities in the pathobiology process, both diseases having poor outcomes. Immune checkpoint PD-L1 has become the target of checkpoint inhibitory therapy that unleashes antitumor T cells and has revolutionized cancer treatment. This is a pilot study exploring membrane immune checkpoint PD-L1 expression in human IPF lung tissue samples and its soluble form, soluble PD-L1 (sPD-L1) plasma concentrations in IPF patients, in order to investigate potential role of PD-L1 as an IPF biomarker. Methods: Twelve human IPF lung tissue samples (formalin-fixed, paraffin-embedded) obtained by surgical biopsy, have been tested for PD-L1 expression by PD-L1 IHC 22C3 pharmDx assay, while plasma samples for examination of sPD-L1 forms, PD-L1 (B7-H1/CD274) blood concentration, originated from 23 patients with IPE who did not undergo surgical biopsy. Results: Membrane PD-L1 expression in IPF lung tissue samples was positive to overexpression of PD-L1 in 9 samples out of 12. Only very few cells in the interstitium have shown a discrete PD-L1 expression, but not of a membrane type. As for sPD-L1 forms, we have found elevated concentrations of sPD-L1 in the serum of IPF patients 314.3 ng/L (117.7-483.1 ng/L), significantly higher compared with healthy control group 91.0 ng/L (52.4-119.7 ng/L), P lt 0.01. Conclusions: For IPF with PD-L1 expression on alveolar macrophages, further studies are necessary to elucidate this phenomenon. Serum sPD-1/PD-L1 is easily detected in clinical practice and should be further evaluated as a potential prognostic or/and predictive biomarker in IPF.
PB  - Ame Publ Co, Shatin
T2  - Journal of Thoracic Disease
T1  - Membrane PD-L1 expression and soluble PD-L1 plasma levels in idiopathic pulmonary fibrosis-a pilot study
VL  - 10
IS  - 12
SP  - 6660
EP  - 6669
DO  - 10.21037/jtd.2018.11.16
ER  - 

@article{
author = "Jovanović, Dragana and Milenković, Marina and Kotur-Stevuljević, Jelena and Marković, Jelena and Ceriman, Vesna and Kontić, Milica and Skodrić-Trifunović, Vesna",
year = "2018",
abstract = "Background: Idiopathic pulmonary fibrosis (IPF) has common risk factors with cancer and significant similarities in the pathobiology process, both diseases having poor outcomes. Immune checkpoint PD-L1 has become the target of checkpoint inhibitory therapy that unleashes antitumor T cells and has revolutionized cancer treatment. This is a pilot study exploring membrane immune checkpoint PD-L1 expression in human IPF lung tissue samples and its soluble form, soluble PD-L1 (sPD-L1) plasma concentrations in IPF patients, in order to investigate potential role of PD-L1 as an IPF biomarker. Methods: Twelve human IPF lung tissue samples (formalin-fixed, paraffin-embedded) obtained by surgical biopsy, have been tested for PD-L1 expression by PD-L1 IHC 22C3 pharmDx assay, while plasma samples for examination of sPD-L1 forms, PD-L1 (B7-H1/CD274) blood concentration, originated from 23 patients with IPE who did not undergo surgical biopsy. Results: Membrane PD-L1 expression in IPF lung tissue samples was positive to overexpression of PD-L1 in 9 samples out of 12. Only very few cells in the interstitium have shown a discrete PD-L1 expression, but not of a membrane type. As for sPD-L1 forms, we have found elevated concentrations of sPD-L1 in the serum of IPF patients 314.3 ng/L (117.7-483.1 ng/L), significantly higher compared with healthy control group 91.0 ng/L (52.4-119.7 ng/L), P lt 0.01. Conclusions: For IPF with PD-L1 expression on alveolar macrophages, further studies are necessary to elucidate this phenomenon. Serum sPD-1/PD-L1 is easily detected in clinical practice and should be further evaluated as a potential prognostic or/and predictive biomarker in IPF.",
publisher = "Ame Publ Co, Shatin",
journal = "Journal of Thoracic Disease",
title = "Membrane PD-L1 expression and soluble PD-L1 plasma levels in idiopathic pulmonary fibrosis-a pilot study",
volume = "10",
number = "12",
pages = "6660-6669",
doi = "10.21037/jtd.2018.11.16"
}

Jovanović, D., Milenković, M., Kotur-Stevuljević, J., Marković, J., Ceriman, V., Kontić, M.,& Skodrić-Trifunović, V.. (2018). Membrane PD-L1 expression and soluble PD-L1 plasma levels in idiopathic pulmonary fibrosis-a pilot study. in Journal of Thoracic Disease
Ame Publ Co, Shatin., 10(12), 6660-6669.
https://doi.org/10.21037/jtd.2018.11.16

Jovanović D, Milenković M, Kotur-Stevuljević J, Marković J, Ceriman V, Kontić M, Skodrić-Trifunović V. Membrane PD-L1 expression and soluble PD-L1 plasma levels in idiopathic pulmonary fibrosis-a pilot study. in Journal of Thoracic Disease. 2018;10(12):6660-6669.
doi:10.21037/jtd.2018.11.16 .

Jovanović, Dragana, Milenković, Marina, Kotur-Stevuljević, Jelena, Marković, Jelena, Ceriman, Vesna, Kontić, Milica, Skodrić-Trifunović, Vesna, "Membrane PD-L1 expression and soluble PD-L1 plasma levels in idiopathic pulmonary fibrosis-a pilot study" in Journal of Thoracic Disease, 10, no. 12 (2018):6660-6669,
https://doi.org/10.21037/jtd.2018.11.16 . .

TY  - JOUR
AU  - Vučinić, Violeta
AU  - Skodrić-Trifunović, Vesna
AU  - Ignjatović, Svetlana
PY  - 2011
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1534
AB  - Purpose of review Calcium metabolism impairments have long been recognized as a complication of sarcoidosis. For more than six decades physicians and investigators have been trying to elucidate this severe problem; nevertheless it seems puzzlingly new for both readers and researchers. Recent findings This review highlights the problems of calcium metabolism in sarcoidosis in relation to vitamin D synthesis, which is definitely altered by granulomatous inflammation. Increasing evidence suggests that vitamin D is an immunomodulating hormone that inhibits both antigen presentation by cells of the innate immune system, and the cytokine release and proliferation of Th1 cells. As calcium homeostasis is primary controlled by levels of vitamin D, parathyroid hormone (PTH) and calcitonin, this literature review emphasizes the role of general immunomodulating properties of vitamin D and the correlation with calcium metabolism impairments, with the special accent on already known interactions with sarcoidosis. Summary Granuloma formation has been related to a failure of the innate immune system. One of the possible explanations is a vitamin D deficiency. The evidence-based findings on calcium metabolism impairments and the interactions with vitamin D might help both clinicians and researchers in developing new strategies.
PB  - Lippincott Williams & Wilkins, Philadelphia
T2  - Current Opinion in Pulmonary Medicine
T1  - How to diagnose and manage difficult problems of calcium metabolism in sarcoidosis: an evidence-based review
VL  - 17
IS  - 5
SP  - 297
EP  - 302
DO  - 10.1097/MCP.0b013e328348b3cb
ER  - 

@article{
author = "Vučinić, Violeta and Skodrić-Trifunović, Vesna and Ignjatović, Svetlana",
year = "2011",
abstract = "Purpose of review Calcium metabolism impairments have long been recognized as a complication of sarcoidosis. For more than six decades physicians and investigators have been trying to elucidate this severe problem; nevertheless it seems puzzlingly new for both readers and researchers. Recent findings This review highlights the problems of calcium metabolism in sarcoidosis in relation to vitamin D synthesis, which is definitely altered by granulomatous inflammation. Increasing evidence suggests that vitamin D is an immunomodulating hormone that inhibits both antigen presentation by cells of the innate immune system, and the cytokine release and proliferation of Th1 cells. As calcium homeostasis is primary controlled by levels of vitamin D, parathyroid hormone (PTH) and calcitonin, this literature review emphasizes the role of general immunomodulating properties of vitamin D and the correlation with calcium metabolism impairments, with the special accent on already known interactions with sarcoidosis. Summary Granuloma formation has been related to a failure of the innate immune system. One of the possible explanations is a vitamin D deficiency. The evidence-based findings on calcium metabolism impairments and the interactions with vitamin D might help both clinicians and researchers in developing new strategies.",
publisher = "Lippincott Williams & Wilkins, Philadelphia",
journal = "Current Opinion in Pulmonary Medicine",
title = "How to diagnose and manage difficult problems of calcium metabolism in sarcoidosis: an evidence-based review",
volume = "17",
number = "5",
pages = "297-302",
doi = "10.1097/MCP.0b013e328348b3cb"
}

Vučinić, V., Skodrić-Trifunović, V.,& Ignjatović, S.. (2011). How to diagnose and manage difficult problems of calcium metabolism in sarcoidosis: an evidence-based review. in Current Opinion in Pulmonary Medicine
Lippincott Williams & Wilkins, Philadelphia., 17(5), 297-302.
https://doi.org/10.1097/MCP.0b013e328348b3cb

Vučinić V, Skodrić-Trifunović V, Ignjatović S. How to diagnose and manage difficult problems of calcium metabolism in sarcoidosis: an evidence-based review. in Current Opinion in Pulmonary Medicine. 2011;17(5):297-302.
doi:10.1097/MCP.0b013e328348b3cb .

Vučinić, Violeta, Skodrić-Trifunović, Vesna, Ignjatović, Svetlana, "How to diagnose and manage difficult problems of calcium metabolism in sarcoidosis: an evidence-based review" in Current Opinion in Pulmonary Medicine, 17, no. 5 (2011):297-302,
https://doi.org/10.1097/MCP.0b013e328348b3cb . .